Back to resultsEvaluation of the Efficacy and Safety of Azeliragon (TTP488) in Patients With Mild Alzheimer's Disease (STEADFAST)
Primary Purpose
Alzheimer's Disease
Status
Terminated
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
Azeliragon
Placebo
Sponsored by
About this trial
This is an interventional treatment trial for Alzheimer's Disease focused on measuring Alzheimer's disease, RAGE, ADAS-cog, CDR-sb
Eligibility Criteria
Inclusion Criteria:
- Diagnosis of probable Alzheimer Disease (AD) with documented evidence of progression of disease
- Mini Mental State Examination (MMSE) score of 21-26, inclusive
- Clinical Dementia Rating global score of 0.5 or 1
- Rosen-Modified Hachinski Ischemia Score less than or equal to 4
- Brain magnetic resonance imaging (MRI) consistent with the diagnosis of probable AD
- Concurrent use of cholinesterase inhibitor or memantine with stable dose for at least 3 months prior to randomization
- Caregiver willing to participate and be able to attend clinic visits with patient
- Ability to ingest oral medications
Exclusion Criteria:
- Significant neurological or psychiatric disease other than Alzheimer's disease
- Participants with evidence or history of severe drug allergies (resulting in dyspnea or severe rash).
- Any contraindications to MRI (e.g., clinically significant claustrophobia, non-removable ferromagnetic implants). Patients with contraindications to MRI may undergo computed tomography (CT) on approval by sponsor.
- Any contraindications to the FDG-PET study (e.g. allergy to any component of the FDG dose) in the cohort undergoing a PET scan.
- Previous exposure to investigational or non-investigational therapies for Alzheimer's disease within 6 months of screening
- History of cancer within the last 5 years except adequately treated cervical carcinoma in-situ, cutaneous basal cell or squamous cell cancer, or non-progressive prostate cancer not requiring treatment
- Women of childbearing potential
- Uncontrolled blood pressure and/or blood pressure above 160/100
- Prescription medical food intended for dietary management of the metabolic processes associated with Alzheimer's disease.
- Diagnosis or history of cerebrovascular stroke, severe carotid stenosis, cerebral hemorrhage, intracranial tumor, subarachnoid hemorrhage.
- Patients with unstable, uncontrolled diabetes (HbA1c > 7.7%) and those requiring insulin.
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
Azeliragon 5mg
Placebo
Arm Description
Azeliragon (TTP488) 5mg orally once daily for 18 months
Placebo orally once daily for 18 months
Outcomes
Primary Outcome Measures
Change From Baseline in Alzheimer's Disease Assessment Scale - Cognitive (ADAS-cog) Total Score
The ADAS-cog is a structured scale (approximately 40 minutes to complete) that evaluates memory, orientation, attention, reasoning, language and constructional praxis (Rosen, 1984). The ADAS-cog scoring range for the version used in this study is from 0 to 70, with higher scores indicating greater cognitive impairment.
Change From Baseline in Clinical Dementia Rating Scale Sum of Boxes (CDR-sb)
The CDR scale is used as a global measure of dementia and is completed by a clinician in the setting of detailed knowledge of the individual patient collected from interviews with the patient and caregiver (Berg, 1988). The CDR describes 5 degrees of impairment in performance on each of 6 categories including memory, orientation, judgment and problem solving, community affairs, home and hobbies, and personal care. CDR ratings are 0 for healthy individuals, 0.5 for questionable dementia and 1, 2 and 3 for mild, moderate and severe dementia as defined in the CDR scale. The scores for each category can also be summed and this is known as the sum of box score (CSR-SB). Sum of box scores range from 0 to 18 with higher scores indicating greater cognitive impairment.
Secondary Outcome Measures
Change From Baseline in Magnetic Resonance Imaging (MRI) Brain Volumetric Measures
Percent of Total Hippocampus Atrophy to Intracranial Volume
Change From Baseline in the Normalized Mean Composite SUVR of the 5 Regions
Extent and severity of brain hypometabolism was assessed centrally at Baseline and Month 18. SUVR PET was designed to make use of FreeSurfer-based segmentations of the brain obtained using the 3DT1 MRI. Following the methods published by Landau and Jagust (Landau SM, Annals of Neurology 2012) and described on the ADNI website (http://adni.loni.usc.edu/methods/pet-analysis-method/), regions were defined in native patient space on the 3DT1 MRI acquired at the Baseline visit and at Month 18 visit. An SUVR measure was computed regionally over five sub-regions (anterior/posterior cingulate, temporal, parietal, frontal and hippocampal areas), normalized to activity in the cerebral white matter. These sub-regions were selected to optimize sensitivity in longitudinal studies. This outcome measure presents the change from baseline in the normalized mean composite SUVR of the 5 regions. A negative change from baseline indicates a decrease (worsening) in brain glucose metabolism/utilization.
Change From Baseline in Alzheimer's Disease Cooperative Study- Activities of Daily Living Inventory (ADCS-ADL)
The ADCS-ADL is an activity of daily living inventory developed by the ADCS to assess functional performance in participants with AD (Galasko et al., 1997). Informants are queried via a structured interview format as to whether participants attempted each item in the inventory during the preceding 4 weeks, as well as their level of performance. Scores range from 0-78 with lower scores indicating greater functional impairment.
Change From Baseline in Mini-Mental State Examination (MMSE)
The MMSE is a brief 30-point test that is used to assess cognition (Folstein, 1975). It is commonly used to screen for dementia. In the time span of about 10 minutes, it samples various functions, including arithmetic, memory and orientation. Scores range from 0-30 with lower scores indicating greater cognitive impairment.
Change From Baseline in Neuropsychiatric Inventory (NPI)
The NPI is a well-validated, reliable, multi-item instrument to assess psychopathology in AD based on an interview with the caregiver (Cummings et al, 1994). It evaluates both the frequency and severity of 12 behavioral areas including delusions, hallucinations, dysphoria (depression) anxiety, agitation/aggression, euphoria, disinhibition, irritability, lability, apathy, aberrant motor behavior, appetite and eating changes and night-time behaviors.
Frequency assessments range from 1 (occasionally, less than once per week) to 4 (very frequently, once or more per day or continuously) as well as severity (1= mild, 2 = moderate, 3 = severe). Distress is rated by the study partner or caregiver and ranges from 0 (no distress) to 5 (very severe or extreme). The overall score and the score for each subscale are the product of severity and frequency. Scores range from 0-144 with higher scores indicating a greater presence of neuropsychiatric symptoms.
Change From Baseline in Dementia Quality of Life (DEMQOL)
The DEMQOL-Proxy questionnaire is a validated and reliable questionnaire that is interview administered and completed by the caregiver about the patient's health related quality of life (Smith et al, 2005). It consists of 31 items representing 5 domains (daily activities and looking after yourself, health and well-being, cognitive functioning, social relationships, and self-concept) and takes approximately 20 minutes to complete. Scores range 31-124 with higher scores indicate better health related quality of life.
Change From Baseline in Continuous Oral Word Association Task (COWAT)
The COWAT is a measure of verbal fluency in which the participant is asked to generate orally as many words as possible that begin with the letters "F", "A", and "S", excluding proper names and different forms of the same word. (Borkowski, 1967, Loonstra 2001) For each letter, the participant is allowed one minute to generate the words. Performance is measured by the total number of correct words produced summed across the three letters. Perseverations (i.e., repetitions of a correct word) and intrusions (i.e., words not beginning with the designated letter) are noted.
Change From Baseline in Category Fluency Test (CFT)
Study participants are given one minute to provide exemplars of the category 'animals'.
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT02080364
Brief Title
Evaluation of the Efficacy and Safety of Azeliragon (TTP488) in Patients With Mild Alzheimer's Disease
Acronym
STEADFAST
Official Title
Randomized, Double-blind, Placebo Controlled, Multi-center Registration Trial to Evaluate the Efficacy and Safety of Azeliragon (TTP488) in Patients With Mild Alzheimer's Disease Receiving Acetylcholinesterase Inhibitors and/or Memantine
Study Type
Interventional
2. Study Status
Record Verification Date
May 2021
Overall Recruitment Status
Terminated
Why Stopped
Not due to safety but due to a lack of efficacy at the 5 mg azeliragon dose.
Study Start Date
April 2015 (Actual)
Primary Completion Date
June 1, 2018 (Actual)
Study Completion Date
June 1, 2018 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
vTv Therapeutics
4. Oversight
Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
This is a study to evaluate the efficacy and safety of azeliragon in patients with mild Alzheimer's disease. Patients will receive either azeliragon or placebo with a patient's participation lasting approximately 18 months.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Alzheimer's Disease
Keywords
Alzheimer's disease, RAGE, ADAS-cog, CDR-sb
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
880 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Azeliragon 5mg
Arm Type
Experimental
Arm Description
Azeliragon (TTP488) 5mg orally once daily for 18 months
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Placebo orally once daily for 18 months
Intervention Type
Drug
Intervention Name(s)
Azeliragon
Other Intervention Name(s)
TTP488
Intervention Description
Azeliragon 5mg administered orally, once daily for 18 months
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Placebo administered orally, once daily for 18 months
Primary Outcome Measure Information:
Title
Change From Baseline in Alzheimer's Disease Assessment Scale - Cognitive (ADAS-cog) Total Score
Description
The ADAS-cog is a structured scale (approximately 40 minutes to complete) that evaluates memory, orientation, attention, reasoning, language and constructional praxis (Rosen, 1984). The ADAS-cog scoring range for the version used in this study is from 0 to 70, with higher scores indicating greater cognitive impairment.
Time Frame
Baseline and 18 months (A-Study); baseline and 12 months (B-Study)
Title
Change From Baseline in Clinical Dementia Rating Scale Sum of Boxes (CDR-sb)
Description
The CDR scale is used as a global measure of dementia and is completed by a clinician in the setting of detailed knowledge of the individual patient collected from interviews with the patient and caregiver (Berg, 1988). The CDR describes 5 degrees of impairment in performance on each of 6 categories including memory, orientation, judgment and problem solving, community affairs, home and hobbies, and personal care. CDR ratings are 0 for healthy individuals, 0.5 for questionable dementia and 1, 2 and 3 for mild, moderate and severe dementia as defined in the CDR scale. The scores for each category can also be summed and this is known as the sum of box score (CSR-SB). Sum of box scores range from 0 to 18 with higher scores indicating greater cognitive impairment.
Time Frame
Baseline and 18 months (A-Study); baseline and 12 months (B-Study)
Secondary Outcome Measure Information:
Title
Change From Baseline in Magnetic Resonance Imaging (MRI) Brain Volumetric Measures
Description
Percent of Total Hippocampus Atrophy to Intracranial Volume
Time Frame
Baseline and 18 months
Title
Change From Baseline in the Normalized Mean Composite SUVR of the 5 Regions
Description
Extent and severity of brain hypometabolism was assessed centrally at Baseline and Month 18. SUVR PET was designed to make use of FreeSurfer-based segmentations of the brain obtained using the 3DT1 MRI. Following the methods published by Landau and Jagust (Landau SM, Annals of Neurology 2012) and described on the ADNI website (http://adni.loni.usc.edu/methods/pet-analysis-method/), regions were defined in native patient space on the 3DT1 MRI acquired at the Baseline visit and at Month 18 visit. An SUVR measure was computed regionally over five sub-regions (anterior/posterior cingulate, temporal, parietal, frontal and hippocampal areas), normalized to activity in the cerebral white matter. These sub-regions were selected to optimize sensitivity in longitudinal studies. This outcome measure presents the change from baseline in the normalized mean composite SUVR of the 5 regions. A negative change from baseline indicates a decrease (worsening) in brain glucose metabolism/utilization.
Time Frame
Baseline to 18 months
Title
Change From Baseline in Alzheimer's Disease Cooperative Study- Activities of Daily Living Inventory (ADCS-ADL)
Description
The ADCS-ADL is an activity of daily living inventory developed by the ADCS to assess functional performance in participants with AD (Galasko et al., 1997). Informants are queried via a structured interview format as to whether participants attempted each item in the inventory during the preceding 4 weeks, as well as their level of performance. Scores range from 0-78 with lower scores indicating greater functional impairment.
Time Frame
Baseline and 18 months (A-Study); baseline and 12 months (B-Study)
Title
Change From Baseline in Mini-Mental State Examination (MMSE)
Description
The MMSE is a brief 30-point test that is used to assess cognition (Folstein, 1975). It is commonly used to screen for dementia. In the time span of about 10 minutes, it samples various functions, including arithmetic, memory and orientation. Scores range from 0-30 with lower scores indicating greater cognitive impairment.
Time Frame
Baseline and 18 months (A-Study); baseline and 12 months (B-Study)
Title
Change From Baseline in Neuropsychiatric Inventory (NPI)
Description
The NPI is a well-validated, reliable, multi-item instrument to assess psychopathology in AD based on an interview with the caregiver (Cummings et al, 1994). It evaluates both the frequency and severity of 12 behavioral areas including delusions, hallucinations, dysphoria (depression) anxiety, agitation/aggression, euphoria, disinhibition, irritability, lability, apathy, aberrant motor behavior, appetite and eating changes and night-time behaviors.
Frequency assessments range from 1 (occasionally, less than once per week) to 4 (very frequently, once or more per day or continuously) as well as severity (1= mild, 2 = moderate, 3 = severe). Distress is rated by the study partner or caregiver and ranges from 0 (no distress) to 5 (very severe or extreme). The overall score and the score for each subscale are the product of severity and frequency. Scores range from 0-144 with higher scores indicating a greater presence of neuropsychiatric symptoms.
Time Frame
Baseline and 18 months (A-Study); baseline and 12 months (B-Study)
Title
Change From Baseline in Dementia Quality of Life (DEMQOL)
Description
The DEMQOL-Proxy questionnaire is a validated and reliable questionnaire that is interview administered and completed by the caregiver about the patient's health related quality of life (Smith et al, 2005). It consists of 31 items representing 5 domains (daily activities and looking after yourself, health and well-being, cognitive functioning, social relationships, and self-concept) and takes approximately 20 minutes to complete. Scores range 31-124 with higher scores indicate better health related quality of life.
Time Frame
Baseline and 18 months (A-Study); baseline and 12 months (B-Study)
Title
Change From Baseline in Continuous Oral Word Association Task (COWAT)
Description
The COWAT is a measure of verbal fluency in which the participant is asked to generate orally as many words as possible that begin with the letters "F", "A", and "S", excluding proper names and different forms of the same word. (Borkowski, 1967, Loonstra 2001) For each letter, the participant is allowed one minute to generate the words. Performance is measured by the total number of correct words produced summed across the three letters. Perseverations (i.e., repetitions of a correct word) and intrusions (i.e., words not beginning with the designated letter) are noted.
Time Frame
Baseline and 18 months (A-Study); baseline and 12 months (B-Study)
Title
Change From Baseline in Category Fluency Test (CFT)
Description
Study participants are given one minute to provide exemplars of the category 'animals'.
Time Frame
Baseline and 18 months (A-Study); baseline and 12 months (B-Study)
10. Eligibility
Sex
All
Minimum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Diagnosis of probable Alzheimer Disease (AD) with documented evidence of progression of disease
Mini Mental State Examination (MMSE) score of 21-26, inclusive
Clinical Dementia Rating global score of 0.5 or 1
Rosen-Modified Hachinski Ischemia Score less than or equal to 4
Brain magnetic resonance imaging (MRI) consistent with the diagnosis of probable AD
Concurrent use of cholinesterase inhibitor or memantine with stable dose for at least 3 months prior to randomization
Caregiver willing to participate and be able to attend clinic visits with patient
Ability to ingest oral medications
Exclusion Criteria:
Significant neurological or psychiatric disease other than Alzheimer's disease
Participants with evidence or history of severe drug allergies (resulting in dyspnea or severe rash).
Any contraindications to MRI (e.g., clinically significant claustrophobia, non-removable ferromagnetic implants). Patients with contraindications to MRI may undergo computed tomography (CT) on approval by sponsor.
Any contraindications to the FDG-PET study (e.g. allergy to any component of the FDG dose) in the cohort undergoing a PET scan.
Previous exposure to investigational or non-investigational therapies for Alzheimer's disease within 6 months of screening
History of cancer within the last 5 years except adequately treated cervical carcinoma in-situ, cutaneous basal cell or squamous cell cancer, or non-progressive prostate cancer not requiring treatment
Women of childbearing potential
Uncontrolled blood pressure and/or blood pressure above 160/100
Prescription medical food intended for dietary management of the metabolic processes associated with Alzheimer's disease.
Diagnosis or history of cerebrovascular stroke, severe carotid stenosis, cerebral hemorrhage, intracranial tumor, subarachnoid hemorrhage.
Patients with unstable, uncontrolled diabetes (HbA1c > 7.7%) and those requiring insulin.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Aaron H Burstein, PharmD
Organizational Affiliation
vTv Therapeutics
Official's Role
Study Director
Facility Information:
City
Phoenix
State/Province
Arizona
ZIP/Postal Code
85004
Country
United States
City
Phoenix
State/Province
Arizona
ZIP/Postal Code
85013
Country
United States
City
Phoenix
State/Province
Arizona
ZIP/Postal Code
85018
Country
United States
City
Tucson
State/Province
Arizona
ZIP/Postal Code
85724
Country
United States
City
Tucson
State/Province
Arizona
ZIP/Postal Code
85741
Country
United States
City
Bellflower
State/Province
California
ZIP/Postal Code
90706
Country
United States
City
Costa Mesa
State/Province
California
ZIP/Postal Code
92626
Country
United States
City
Fullerton
State/Province
California
ZIP/Postal Code
92835
Country
United States
City
Glendale
State/Province
California
ZIP/Postal Code
91206
Country
United States
City
Imperial
State/Province
California
ZIP/Postal Code
92251
Country
United States
City
Irvine
State/Province
California
ZIP/Postal Code
92614
Country
United States
City
Laguna Hills
State/Province
California
ZIP/Postal Code
92653
Country
United States
City
Long Beach
State/Province
California
ZIP/Postal Code
90806
Country
United States
City
Long Beach
State/Province
California
ZIP/Postal Code
90807
Country
United States
City
Orange
State/Province
California
ZIP/Postal Code
92868
Country
United States
City
Riverside
State/Province
California
ZIP/Postal Code
92506
Country
United States
City
San Bernardino
State/Province
California
ZIP/Postal Code
92408
Country
United States
City
San Francisco
State/Province
California
ZIP/Postal Code
94114
Country
United States
City
Santa Ana
State/Province
California
ZIP/Postal Code
92705
Country
United States
City
Atlantis
State/Province
Florida
ZIP/Postal Code
33462
Country
United States
City
Brooksville
State/Province
Florida
ZIP/Postal Code
34601
Country
United States
City
Delray Beach
State/Province
Florida
ZIP/Postal Code
33445
Country
United States
City
Hallandale Beach
State/Province
Florida
ZIP/Postal Code
33009
Country
United States
City
Hialeah
State/Province
Florida
ZIP/Postal Code
33016
Country
United States
City
Jacksonville
State/Province
Florida
ZIP/Postal Code
32216
Country
United States
City
Lake Worth
State/Province
Florida
ZIP/Postal Code
33449
Country
United States
City
Leesburg
State/Province
Florida
ZIP/Postal Code
34748
Country
United States
City
Miami Beach
State/Province
Florida
ZIP/Postal Code
33140
Country
United States
City
Miami Lakes
State/Province
Florida
ZIP/Postal Code
33014
Country
United States
City
Miami Lakes
State/Province
Florida
ZIP/Postal Code
33016
Country
United States
City
Miami
State/Province
Florida
ZIP/Postal Code
33122
Country
United States
City
Miami
State/Province
Florida
ZIP/Postal Code
33137
Country
United States
City
Orlando
State/Province
Florida
ZIP/Postal Code
32806
Country
United States
City
Pensacola
State/Province
Florida
ZIP/Postal Code
32503
Country
United States
City
Sarasota
State/Province
Florida
ZIP/Postal Code
34243
Country
United States
City
Sunrise
State/Province
Florida
ZIP/Postal Code
33351
Country
United States
City
Atlanta
State/Province
Georgia
ZIP/Postal Code
30331
Country
United States
City
Columbus
State/Province
Georgia
ZIP/Postal Code
31909
Country
United States
City
Chicago
State/Province
Illinois
ZIP/Postal Code
60640
Country
United States
City
Fairway
State/Province
Kansas
ZIP/Postal Code
66205
Country
United States
City
Prairie Village
State/Province
Kansas
ZIP/Postal Code
66201
Country
United States
City
Lexington
State/Province
Kentucky
ZIP/Postal Code
40504
Country
United States
City
Baltimore
State/Province
Maryland
ZIP/Postal Code
21208
Country
United States
City
Newton
State/Province
Massachusetts
ZIP/Postal Code
02459
Country
United States
City
Plymouth
State/Province
Massachusetts
ZIP/Postal Code
02360
Country
United States
City
Quincy
State/Province
Massachusetts
ZIP/Postal Code
01269
Country
United States
City
Hattiesburg
State/Province
Mississippi
ZIP/Postal Code
39401
Country
United States
City
Creve Coeur
State/Province
Missouri
ZIP/Postal Code
63141
Country
United States
City
Princeton
State/Province
New Jersey
ZIP/Postal Code
08540
Country
United States
City
Albuquerque
State/Province
New Mexico
ZIP/Postal Code
87109
Country
United States
City
Albany
State/Province
New York
ZIP/Postal Code
12208
Country
United States
City
Lake Success
State/Province
New York
ZIP/Postal Code
11042
Country
United States
City
New York
State/Province
New York
ZIP/Postal Code
10032
Country
United States
City
Staten Island
State/Province
New York
ZIP/Postal Code
10312
Country
United States
City
Charlotte
State/Province
North Carolina
ZIP/Postal Code
28270
Country
United States
City
Raleigh
State/Province
North Carolina
ZIP/Postal Code
27607
Country
United States
City
Wilmington
State/Province
North Carolina
ZIP/Postal Code
28401
Country
United States
City
Winston-Salem
State/Province
North Carolina
ZIP/Postal Code
27157
Country
United States
City
Canton
State/Province
Ohio
ZIP/Postal Code
44718
Country
United States
City
Shaker Heights
State/Province
Ohio
ZIP/Postal Code
44122
Country
United States
City
Oklahoma City
State/Province
Oklahoma
ZIP/Postal Code
73103
Country
United States
City
Oklahoma City
State/Province
Oklahoma
ZIP/Postal Code
73118
Country
United States
City
Portland
State/Province
Oregon
ZIP/Postal Code
97210
Country
United States
City
Portland
State/Province
Oregon
ZIP/Postal Code
97225
Country
United States
City
Media
State/Province
Pennsylvania
ZIP/Postal Code
19063
Country
United States
City
Norristown
State/Province
Pennsylvania
ZIP/Postal Code
19403
Country
United States
City
Plains
State/Province
Pennsylvania
ZIP/Postal Code
18705
Country
United States
City
East Providence
State/Province
Rhode Island
ZIP/Postal Code
02914
Country
United States
City
East Providence
State/Province
Rhode Island
ZIP/Postal Code
02916
Country
United States
City
Charleston
State/Province
South Carolina
ZIP/Postal Code
24901
Country
United States
City
Mount Pleasant
State/Province
South Carolina
ZIP/Postal Code
29464
Country
United States
City
Cordova
State/Province
Tennessee
ZIP/Postal Code
38018
Country
United States
City
Nashville
State/Province
Tennessee
ZIP/Postal Code
37203
Country
United States
City
Dallas
State/Province
Texas
ZIP/Postal Code
75231
Country
United States
City
San Antonio
State/Province
Texas
ZIP/Postal Code
78229
Country
United States
City
San Antonio
State/Province
Texas
ZIP/Postal Code
78232
Country
United States
City
Wichita Falls
State/Province
Texas
ZIP/Postal Code
76309
Country
United States
City
Murray
State/Province
Utah
ZIP/Postal Code
84123
Country
United States
City
Kirkland
State/Province
Washington
ZIP/Postal Code
98201
Country
United States
City
Richland
State/Province
Washington
ZIP/Postal Code
99352
Country
United States
City
Southport
State/Province
Queensland
ZIP/Postal Code
4222
Country
Australia
City
Caulfield
State/Province
Victoria
ZIP/Postal Code
3162
Country
Australia
City
Geelong
State/Province
Victoria
ZIP/Postal Code
3220
Country
Australia
City
Heidelberg West
State/Province
Victoria
ZIP/Postal Code
3081
Country
Australia
City
Nedlands
State/Province
Western Australia
ZIP/Postal Code
6009
Country
Australia
City
West Perth
State/Province
Western Australia
ZIP/Postal Code
6005
Country
Australia
City
Calgary
State/Province
Alberta
ZIP/Postal Code
T2N 4Z6
Country
Canada
City
Medicine Hat
State/Province
Alberta
ZIP/Postal Code
T1B 4E7
Country
Canada
City
Kentville
State/Province
Nova Scotia
ZIP/Postal Code
B4N4K9
Country
Canada
City
Chatham
State/Province
Ontario
ZIP/Postal Code
N7L 1C1
Country
Canada
City
London
State/Province
Ontario
ZIP/Postal Code
N6C 5J1
Country
Canada
City
Toronto
State/Province
Ontario
ZIP/Postal Code
M3B 257
Country
Canada
City
Gatineau
State/Province
Quebec
ZIP/Postal Code
J8T 8J1
Country
Canada
City
Greenfield Park
State/Province
Quebec
ZIP/Postal Code
J4V2J2
Country
Canada
City
Cork
Country
Ireland
City
Dublin 8
Country
Ireland
City
Galway
Country
Ireland
City
Christchurch
State/Province
Canterbury
ZIP/Postal Code
8011
Country
New Zealand
City
Christchurch
State/Province
Canterbury
ZIP/Postal Code
8022
Country
New Zealand
City
Cape Town
ZIP/Postal Code
7405
Country
South Africa
City
Cape Town
ZIP/Postal Code
7530
Country
South Africa
City
Johannesburg
ZIP/Postal Code
2196
Country
South Africa
City
St. George
ZIP/Postal Code
6529
Country
South Africa
City
Glasgow
ZIP/Postal Code
G20 OAXA
Country
United Kingdom
City
London
ZIP/Postal Code
W1G 9RU
Country
United Kingdom
City
London
ZIP/Postal Code
WC1X 8QD
Country
United Kingdom
City
Manchester
ZIP/Postal Code
M8 5RB
Country
United Kingdom
City
Northampton
ZIP/Postal Code
NN5 6UD
Country
United Kingdom
City
Oxford
ZIP/Postal Code
OX3 7JX
Country
United Kingdom
City
Penarth
ZIP/Postal Code
CF64 2XX
Country
United Kingdom
City
Preston
ZIP/Postal Code
PR2 9HT
Country
United Kingdom
City
Sheffield
ZIP/Postal Code
S5 7JT
Country
United Kingdom
City
Southhampton
ZIP/Postal Code
SO30 3JB
Country
United Kingdom
City
Swindon
ZIP/Postal Code
SN3 6BW
Country
United Kingdom
City
Warrington
ZIP/Postal Code
WA2 8WA
Country
United Kingdom
12. IPD Sharing Statement
Links:
URL
http://www.livingsteadfast.com
Description
Related Info
Learn more about this trial
Evaluation of the Efficacy and Safety of Azeliragon (TTP488) in Patients With Mild Alzheimer's Disease
We'll reach out to this number within 24 hrs